Five Proven Systems Reducing Financial Toxicity at Diagnosis.
Financial toxicity isn’t a side effect of cancer treatment. It’s a predictable outcome of a care model that was never built to handle the cost of staying alive. We engineered…
How AI is Quietly Shaping Oncology – One Workflow at a Time
- Post category:Pan Cancer/Survivorship
- Reading time:4 mins read
Every oncologist today faces the same silent pressures:Infusion chairs full. Charts unfinished. Trial slots empty. Scans waiting for review. AI isn’t the future — it’s the quiet force turning those…
Germline Testing: The Therapeutic Biomarker You Can’t Afford to Miss
- Post category:Breast Cancer/Digestive (CRC, Stomach) System/Genitourinary (Prostate, Bladder) System/Gynecologic Cancer/Melanoma/Respiratory (Lung, Bronchus) System
- Reading time:2 mins read
You may already be ordering germline testing at rates well above the national average — but across the U.S., most eligible patients still aren’t tested: Ovarian cancer: ~39% receive germline…
How ACCURE Closed Racial Survival Gaps in Cancer — And How CMS PIN Codes Scale It
- Post category:Breast Cancer/Pan Cancer/Respiratory (Lung, Bronchus) System/Supportive Oncology
- Reading time:4 mins read
You’ve seen the survival gaps. You’ve felt the impact. And the question that follows is both urgent and fair:What exactly can you do about it — in your clinic, with…
Operationalizing Early Palliative Care: Systems, Codes, and Metrics for Oncology Success
- Post category:Pan Cancer/Supportive Oncology/Survivorship
- Reading time:5 mins read
You know palliative care isn’t an end-of-life intervention. It’s a proactive, evidence-based system that extends survival, preserves dose intensity, and minimizes avoidable treatment disruptions. So, here's the real question: How…
The Immunotherapy Clock Has Moved
- Post category:Breast Cancer/Genitourinary (Prostate, Bladder) System/Head & Neck Cancers/Pan Cancer/Respiratory (Lung, Bronchus) System/Supportive Oncology/Survivorship
- Reading time:3 mins read
Checkpoint inhibitors are no longer reserved for late-stage salvage. The clearest signal from recent meetings and trials is this: the greatest survival benefit may be increasingly found in neoadjuvant and perioperative settings. This…